Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Ultimate Products revenue falls as consumers spend less

(Sharecast News) - Ultimate Products reported a 3.4% drop in annual revenue to £150.1m for the year ended 31 July, as weaker demand for general merchandise offset growth in its core brands. Sales of the group's own UP brands, including Salter and Beldray, rose 4.3% to £121.9m, while licensed brand sales increased 19.2% to £14.4m.

However, third-party clearance and own-label sales fell 48% to £13.8m, following a strong prior year driven by supplier overstock clearances.

Unaudited adjusted EBITDA fell 31% to £12.5m, reflecting an additional £3.1m in freight costs, while operating costs were broadly flat at £22.3m.

Net bank debt rose to £14.1m, representing 1.1 times adjusted EBITDA, slightly above the group's 1.0x target.

Trading in the current financial year is in line with expectations.

The London-listed firm said its board was also reviewing whether to shift its listing from the London Stock Exchange's main market to AIM, citing the potential to attract new investors at its current market capitalisation.

"We continue to operate in a challenging environment, with many consumers prioritising saving over spending," said chief executive Andrew Gossage.

"Although overall revenue declined, we are encouraged by the growth in sales of our UP brands, which remain a key differentiator and the driver of long-term value creation, both in the UK and internationally."

At 1112 BST, shares in Ultimate Products were down 2.02% at 53.4p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.